SCHEMBL5337605

SCHEMBL5337605

CCN(CC(=O)O)Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.54
KDM4E B2RXH2 3/20 0.51
BCHE P06276 3/20 0.51
ACHE P22303 3/20 0.51
TDP1 Q9NUW8 1/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPT P10636 1/20 0.51
CNR2 P34972 1/20 0.50
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
MAOB P27338 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28346088 0.98 LMNA (0.53) LMNAL3MBTL1KDM4EBCHEACHE
SCHEMBL212272 0.90 AKR1B1 (0.52) LMNATDP1ALDH1A1CA12TSHR
SCHEMBL186172 0.88 MEP1B (0.50) LMNATDP1ALDH1A1CA12
Ammonia Solution, Strong SCHEMBL27504556 0.86 MEP1B (0.49) LMNATDP1ALDH1A1CA12
SCHEMBL8415629 0.85 LMNA (0.51) LMNAL3MBTL1KDM4EBCHEACHE
SCHEMBL5541857 0.85 RORC (0.56) LMNABCHEACHECA12TSHR
SCHEMBL16520408 0.85 NPC1 (0.47) LMNAL3MBTL1BCHEACHEALDH1A1
SCHEMBL11586184 0.84 MEP1B (0.47) LMNATDP1ALDH1A1CA12
SCHEMBL2799777 0.84 TDP1 (0.52) LMNAKDM4ETDP1ALDH1A1CA12
SCHEMBL2284795 0.82 TDP1 (0.56) LMNAKDM4ETDP1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118005569-B 6-Aminoquinoxaline compound and preparation method and application thereof 华南理工大学 2026-05-19 CN claimed
EP-3994238-B1 LUBRICATING COMPOSITIONS CONTAINING BASIC ASHLESS ADDITIVES LUBRIZOL CORP (US) 2024-03-13 EP claimed
CN-110734393-B Preparation method of N-benzyl-3-oxopiperidine-4-carboxylic acid ethyl ester hydrochloride 南京恒远科技开发有限公司 2022-02-25 CN claimed
CN-110734393-A Preparation method of N-benzyl-3-oxopiperidine-4-carboxylic acid ethyl ester hydrochloride 南京恒远科技开发有限公司 2020-01-31 CN claimed
CN-110698356-A Preparation and purification method of N-benzyl glycine ethyl ester 南京恒远科技开发有限公司 2020-01-17 CN claimed
US-20130165446-A1 BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE HORIKOSHI, HIROYOSHI (CA) 2013-06-27 US claimed
EP-2581373-A1 BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE Fujita, Takashi (JP) 2013-04-17 EP claimed
CN-118005569-B 6-Aminoquinoxaline compound and preparation method and application thereof 华南理工大学 2026-05-19 CN disclosed
CN-118005569-A 6-Aminoquinoxaline compound and preparation method and application thereof 华南理工大学 2024-05-10 CN disclosed
WO-2023226902-A1 PREPARATION METHOD FOR KRAS G12C INHIBITOR AND INTERMEDIATE THEREOF 苏州泽璟生物制药股份有限公司 2023-11-30 WO disclosed
CN-109384778-B Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder 赛克里翁治疗有限公司 2022-12-13 CN disclosed
CN-115368383-A Condensed nitrogen-containing heterocyclic compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2022-11-22 CN disclosed
CN-110016020-B Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof 赛克里翁治疗有限公司 2022-07-26 CN disclosed
WO-2002064547-A2 ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed
WO-2001046200-A1 NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES ASTRAZENECA AB (SE) 2001-06-28 WO disclosed
US-5221665-A N-substituted amides BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1993-06-22 US disclosed
EP-0369391-A2 N-substituted amides BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 1990-05-23 EP disclosed
US-4534904-A Process for producing N-phosphonomethylglycine CIBA-GEIGY CORPORATION (US) 1985-08-13 US disclosed
US-4486358-A Process for producing N-phosphonomethylglycine CIBA-GEIGY CORPORATION (US) 1984-12-04 US disclosed
US-4369142-A Process for producing N-phosphonomethylglycine CIBA-GEIGY CORPORATION (US) 1983-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165446-A1 BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE PPARG, PPARA, PPARD LMNA 3164/4885L3MBTL1 3137/4885KDM4E 1152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.